Yarrow Bioscience (NASDAQ:YARW) Sees Large Drop in Short Interest

Yarrow Bioscience (NASDAQ:YARW) was the recipient of a large drop in short interest in July. As of July 31st, there was short interest totaling 12,582 shares, a drop of 93.2% from the July 15th total of 183,974 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily volume of 38,657 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Ratings Changes

A number of research firms have issued reports on YARW. BTIG Research started coverage on shares of Yarrow Bioscience in a report on Monday, August 3rd. They issued a “buy” rating and a $58.00 target price on the stock. TD Cowen initiated coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $58.00.

Yarrow Bioscience Price Performance

NASDAQ:YARW traded down $0.05 during mid-day trading on Thursday, reaching $42.72. The company’s stock had a trading volume of 13,552 shares, compared to its average volume of 32,418. Yarrow Bioscience has a twelve month low of $14.02 and a twelve month high of $46.95.

Yarrow Bioscience (NASDAQ:YARW) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.14) earnings per share for the quarter. Yarrow Bioscience had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.